Developer docs
API playgroundTry for free, no card

Search company profiles

Imbria Pharmaceuticals

Full company profile

uuid00004ya

Namestring
Imbria Pharmaceuticals
Legal namestring
Imbria Pharmaceuticals, Inc.
Websiteurl
imbria.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Imbria Pharmaceuticals is a privately held, clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, founded around 2018 and developing a single lead asset, ninerafaxstat, for serious cardiovascular diseases. The company targets patients with non-obstructive hypertrophic cardiomyopathy (nHCM, approximately 250,000-400,000 US patients) as its primary indication, with secondary development in heart failure with preserved ejection fraction (HFpEF, affecting over 6.7 million Americans) and stable angina. The therapeutic hypothesis is that cardiovascular disease is driven in part by impaired cardiac energetics, and that modulating myocardial substrate utilization could address an underlying disease mechanism not targeted by existing hemodynamic therapies.

Ninerafaxstat is a partial fatty acid oxidation (pFOX) inhibitor that shifts the heart's metabolic preference from fatty acids toward glucose, increasing mitochondrial ATP generation efficiency per unit of oxygen consumed. The drug is orally administered with no dose titration or monitoring required, has no clinically significant drug-drug interactions, and does not produce adverse hemodynamic effects (no impact on heart rate, blood pressure, or ejection fraction), making it combinable with standard-of-care cardiovascular therapies. Imbria has used hyperpolarized multi-nuclear MR spectroscopy to directly measure cardiac PCr/ATP ratios in the IMPROVE-DiCE Phase 2a trial, and Phase 2 data has shown statistically significant improvements in KCCQ-CSS (9.3 point LS mean difference), ventilatory efficiency (VE/VCO2 slope -2.1), 6-minute walk distance (~14m), and LV stroke volume augmentation (~188%). The current FORTITUDE-HCM Phase 2b trial is enrolling approximately 165 patients globally across US sites with planned UK and EU expansion, supported by a research partnership with the University of Oxford.

Imbria is pre-revenue with no approved products, no commercial sales, and no current pricing. The business model contemplates future pharmaceutical product sales upon regulatory approval, distributed through standard pharmacy and hospital channels with enterprise field sales targeting cardiologists and heart failure specialists. Operations are funded by venture capital, with a $57.5 million Series B led by Deep Track Capital in April 2025 extended in November 2025 with new investor AXA IM Alts, building on prior Series A rounds led by RA Capital Management and Sanofi Ventures. The company holds FDA Orphan Drug Designation for ninerafaxstat in symptomatic nHCM (June 2026) and operates a clinical-stage organization of approximately 1-10 disclosed senior leaders under CEO Alvin Shih and CMO Albert Kim.

Short descriptiontext

Imbria Pharmaceuticals is a Boston-based, clinical-stage biopharmaceutical company developing ninerafaxstat, a first-in-class partial fatty acid oxidation inhibitor that improves cardiac energetics, for patients with non-obstructive hypertrophic cardiomyopathy and heart failure with preserved ejection fraction.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cardiovascular therapeutics, cardiac energetics drugs, cardiometabolic disease treatments, heart failure therapy, clinical-stage biotechnology
Industry3 codes
PRIMARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAKABAJ
Cardiac Rehabilitation & Secondary Prevention
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Mining & Quarrying Of Nonmetallic Minerals (No Fuels)1400
Product category
Cardiovascular Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Ninerafaxstat commercialization
TypeOne Time License
Description

Imbria is a clinical-stage biopharmaceutical company with no current revenue. The company is developing ninerafaxstat for cardiovascular indications including non-obstructive hypertrophic cardiomyopathy (nHCM) and heart failure with preserved ejection fraction (HFpEF). Future revenue will come from pharmaceutical product sales upon regulatory approval.

imbria.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Imbria Pharmaceuticals is developing ninerafaxstat, a first-in-class partial fatty acid oxidation (pFOX) inhibitor that targets cardiac energy metabolism. The oral drug shifts cardiac substrate utilization from fatty acids to glucose, enhancing mitochondrial ATP production efficiency. It is being advanced through clinical trials for non-obstructive hypertrophic cardiomyopathy (nHCM), heart failure with preserved ejection fraction (HFpEF), and stable angina, addressing fundamental energy deficits in cardiovascular disease.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Statistically significant improvement in KCCQ-CSS score with 9.3 point LS mean difference (p=0.04) in patients with baseline KCCQ-CSS ≤80 in IMPROVE-HCM trial
+4 more records
Product overview1 text field

Imbria Pharmaceuticals is a clinical-stage biotechnology company developing a single lead product candidate, ninerafaxstat, a novel partial fatty acid oxidation (pFOX) inhibitor. The drug is designed to improve cardiac energetics by shifting the heart's fuel preference from fatty acids to glucose, enhancing mitochondrial ATP production. Ninerafaxstat is being advanced through Phase 2b clinical trials (FORTITUDE-HCM) for non-obstructive hypertrophic cardiomyopathy (nHCM), with additional development planned for heart failure with preserved ejection fraction (HFpEF) and stable angina.

Product and service1 record
1Ninerafaxstat
CategoryInvestigational Cardiovascular Pharmaceutical
Description

Ninerafaxstat is an oral, first-in-class partial fatty acid oxidation (pFOX) inhibitor designed as a cardiac mitotrope that shifts the heart's metabolic preference from fatty acids to glucose, producing more ATP per unit of oxygen consumed. The drug requires no dose titration or monitoring, has no clinically significant drug-drug interactions, and can be used on top of standard of care cardiovascular treatments. It is being developed for patients with non-obstructive hypertrophic cardiomyopathy (nHCM), heart failure with preserved ejection fraction (HFpEF), and stable angina. The FORTITUDE-HCM Phase 2b trial is currently enrolling approximately 165 patients globally.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-16
Description

Partnership with HCMA to support recruitment for FORTITUDE-HCM Phase 2b clinical trial evaluating ninerafaxstat in non-obstructive hypertrophic cardiomyopathy. HCMA will support trial recruitment by educating the HCM community through outreach programs, conferences, patient communications, and surveys to help connect patients and clinicians with trial information and enrollment resources.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-09
Description

Clinical trial partnership for IMPROVE-DiCE Phase 2a trial conducted at Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Radcliffe Department of Medicine at the University of Oxford, UK. Led by Professor Oliver Rider.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Imbria Pharmaceuticals

Cardiovascular Pharmaceuticalsimbria.com

Imbria Pharmaceuticals is a Boston-based, clinical-stage biopharmaceutical company developing ninerafaxstat, a first-in-class partial fatty acid oxidation inhibitor that improves cardiac energetics, for patients with non-obstructive hypertrophic cardiomyopathy and heart failure with preserved ejection fraction.

What Imbria Pharmaceuticals does

Imbria Pharmaceuticals is a privately held, clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, founded around 2018 and developing a single lead asset, ninerafaxstat, for serious cardiovascular diseases. The company targets patients with non-obstructive hypertrophic cardiomyopathy (nHCM, approximately 250,000-400,000 US patients) as its primary indication, with secondary development in heart failure with preserved ejection fraction (HFpEF, affecting over 6.7 million Americans) and stable angina. The therapeutic hypothesis is that cardiovascular disease is driven in part by impaired cardiac energetics, and that modulating myocardial substrate utilization could address an underlying disease mechanism not targeted by existing hemodynamic therapies.

Ninerafaxstat is a partial fatty acid oxidation (pFOX) inhibitor that shifts the heart's metabolic preference from fatty acids toward glucose, increasing mitochondrial ATP generation efficiency per unit of oxygen consumed. The drug is orally administered with no dose titration or monitoring required, has no clinically significant drug-drug interactions, and does not produce adverse hemodynamic effects (no impact on heart rate, blood pressure, or ejection fraction), making it combinable with standard-of-care cardiovascular therapies. Imbria has used hyperpolarized multi-nuclear MR spectroscopy to directly measure cardiac PCr/ATP ratios in the IMPROVE-DiCE Phase 2a trial, and Phase 2 data has shown statistically significant improvements in KCCQ-CSS (9.3 point LS mean difference), ventilatory efficiency (VE/VCO2 slope -2.1), 6-minute walk distance (~14m), and LV stroke volume augmentation (~188%). The current FORTITUDE-HCM Phase 2b trial is enrolling approximately 165 patients globally across US sites with planned UK and EU expansion, supported by a research partnership with the University of Oxford.

Imbria is pre-revenue with no approved products, no commercial sales, and no current pricing. The business model contemplates future pharmaceutical product sales upon regulatory approval, distributed through standard pharmacy and hospital channels with enterprise field sales targeting cardiologists and heart failure specialists. Operations are funded by venture capital, with a $57.5 million Series B led by Deep Track Capital in April 2025 extended in November 2025 with new investor AXA IM Alts, building on prior Series A rounds led by RA Capital Management and Sanofi Ventures. The company holds FDA Orphan Drug Designation for ninerafaxstat in symptomatic nHCM (June 2026) and operates a clinical-stage organization of approximately 1-10 disclosed senior leaders under CEO Alvin Shih and CMO Albert Kim.

Imbria Pharmaceuticals firmographics

Firmographics
Name
Imbria Pharmaceuticals
Legal name
Imbria Pharmaceuticals, Inc.
Website
https://imbria.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Imbria Pharmaceuticals is a Boston-based, clinical-stage biopharmaceutical company developing ninerafaxstat, a first-in-class partial fatty acid oxidation inhibitor that improves cardiac energetics, for patients with non-obstructive hypertrophic cardiomyopathy and heart failure with preserved ejection fraction.
Ownership category
akta.pro rank

Imbria Pharmaceuticals industry classification

Industry
Product category
Cardiovascular Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Mining & Quarrying Of Nonmetallic Minerals (No Fuels) (1400)
akta.pro industry
PRIMARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAKABAJ
Cardiac Rehabilitation & Secondary Prevention

Keywords

  • Cardiovascular therapeutics
  • Cardiac energetics drugs
  • Cardiometabolic disease treatments
  • Heart failure therapy
  • Clinical-stage biotechnology

Where Imbria Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Imbria Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Ninerafaxstat commercialization: Imbria is a clinical-stage biopharmaceutical company with no current revenue. The company is developing ninerafaxstat for cardiovascular indications including non-obstructive hypertrophic cardiomyopathy (nHCM) and heart failure with preserved ejection fraction (HFpEF). Future revenue will come from pharmaceutical product sales upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Imbria Pharmaceuticals product offering

Product offering

Core offering

Imbria Pharmaceuticals is developing ninerafaxstat, a first-in-class partial fatty acid oxidation (pFOX) inhibitor that targets cardiac energy metabolism. The oral drug shifts cardiac substrate utilization from fatty acids to glucose, enhancing mitochondrial ATP production efficiency. It is being advanced through clinical trials for non-obstructive hypertrophic cardiomyopathy (nHCM), heart failure with preserved ejection fraction (HFpEF), and stable angina, addressing fundamental energy deficits in cardiovascular disease.

Product overview

Imbria Pharmaceuticals is a clinical-stage biotechnology company developing a single lead product candidate, ninerafaxstat, a novel partial fatty acid oxidation (pFOX) inhibitor. The drug is designed to improve cardiac energetics by shifting the heart's fuel preference from fatty acids to glucose, enhancing mitochondrial ATP production. Ninerafaxstat is being advanced through Phase 2b clinical trials (FORTITUDE-HCM) for non-obstructive hypertrophic cardiomyopathy (nHCM), with additional development planned for heart failure with preserved ejection fraction (HFpEF) and stable angina.

Differentiator

Problem solved

Functional benefit

Products and services

  • Ninerafaxstat Ninerafaxstat is an oral, first-in-class partial fatty acid oxidation (pFOX) inhibitor designed as a cardiac mitotrope that shifts the heart's metabolic preference from fatty acids to glucose, producing more ATP per unit of oxygen consumed. The drug requires no dose titration or monitoring, has no clinically significant drug-drug interactions, and can be used on top of standard of care cardiovascular treatments. It is being developed for patients with non-obstructive hypertrophic cardiomyopathy (nHCM), heart failure with preserved ejection fraction (HFpEF), and stable angina. The FORTITUDE-HCM Phase 2b trial is currently enrolling approximately 165 patients globally.

Quantifiable outcome

  • Statistically significant improvement in KCCQ-CSS score with 9.3 point LS mean difference (p=0.04) in patients with baseline KCCQ-CSS ≤80 in IMPROVE-HCM trial
  • +4 more outcomes

Companies that use Imbria Pharmaceuticals

Customer profile

Segments2 records

Ideal customer profiles2 records

Imbria Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Imbria Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Hypertrophic Cardiomyopathy Association (HCMA)coreStrategic or Co-development Partner · 16 October 2025Partnership with HCMA to support recruitment for FORTITUDE-HCM Phase 2b clinical trial evaluating ninerafaxstat in non-obstructive hypertrophic cardiomyopathy. HCMA will support trial recruitment by educating the HCM community through outreach programs, conferences, patient communications, and surveys to help connect patients and clinicians with trial information and enrollment resources.
  • University of OxfordcoreStrategic or Co-development Partner · 9 January 2023Clinical trial partnership for IMPROVE-DiCE Phase 2a trial conducted at Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Radcliffe Department of Medicine at the University of Oxford, UK. Led by Professor Oliver Rider.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Imbria Pharmaceuticals competitors and assessment

Company assessment

Market position

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Imbria Pharmaceuticals social profiles

Digital presence

Imbria Pharmaceuticals compliance and trust

Trust signal

Compliance1 record

Imbria Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Imbria Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles14 records

Imbria Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Imbria Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Imbria Pharmaceuticals

What does Imbria Pharmaceuticals do?

Imbria Pharmaceuticals is developing ninerafaxstat, a first-in-class partial fatty acid oxidation (pFOX) inhibitor that targets cardiac energy metabolism. The oral drug shifts cardiac substrate utilization from fatty acids to glucose, enhancing mitochondrial ATP production efficiency. It is being advanced through clinical trials for non-obstructive hypertrophic cardiomyopathy (nHCM), heart failure with preserved ejection fraction (HFpEF), and stable angina, addressing fundamental energy deficits in cardiovascular disease.

Is Imbria Pharmaceuticals a public or private company?

Imbria Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.

When was Imbria Pharmaceuticals founded?

Imbria Pharmaceuticals was founded in 2021. It employs 11 to 50 people.

Where is Imbria Pharmaceuticals based?

Imbria Pharmaceuticals is headquartered in Boston, United States, in the North America region.

How does Imbria Pharmaceuticals make money?

One revenue line is on record: ninerafaxstat commercialization.

Does Imbria Pharmaceuticals have an API?

No public API is recorded for Imbria Pharmaceuticals.

What industry is Imbria Pharmaceuticals in?

Imbria Pharmaceuticals's product category is Cardiovascular Pharmaceuticals. Its primary akta.pro industry code is HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals, with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 3254 and its SIC code is 1400.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireImbria Pharmaceuticals Receives FDA Orphan Drug Designation for Ninerafaxstat for Symptomatic Non-Obstructive Hypertrophic CardiomyopathyThe FDA granted orphan drug designation to Imbria's ninerafaxstat for symptomatic non-obstructive hypertrophic cardiomyopathy. The designation provides development incentives and potential market exclusivity, with topline data expected in the first half of 2027.SecSEC FORM DImbria Pharmaceuticals, Inc., a Delaware-incorporated biotechnology company headquartered in Boston, Massachusetts, filed an amended Form D notice with the SEC for an exempt offering of equity securities under Rule 506(b). The filing indicates a total offering amount of $144,195,814, with $66,695,817 already sold to 10 investors, leaving approximately $77.5 million remaining to be sold. The filing was signed on December 16, 2025, by Secretary Komal Joshi, with first sales recorded on March 10, 2025.Pulse 2.0Imbria Pharmaceuticals: Series B Funding Raised And New Board Members Added To Advance Cardiovascular Therapeutic NinerafaxstatImbria Pharmaceuticals has expanded its Series B financing with the addition of new investor AXA IM Alts, joining an existing investor group that includes RA Capital, SV Health Investors, Deep Track Capital, AN Ventures, Catalio Capital Management, and Cytokinetics. As part of the financing, AXA IM Alts executive Zina Affas Besse and AN Ventures Managing Partner Ken Horne have joined Imbria's Board of Directors. The funding will support ongoing clinical programs including the global FORTITUDE-HCM Phase 2b trial for the company's lead therapeutic candidate ninerafaxstat, a first-in-class treatment for cardiovascular diseases.GlobeNewswireImbria Pharmaceuticals Announces Extension of Series B Financing to Advance Ninerafaxstat for Cardiovascular DiseasesImbria Pharmaceuticals announced that AXA IM Alts has joined its upsized Series B financing round, extending the existing syndicate of investors including RA Capital, SV Health Investors, Deep Track Capital, AN Ventures, Catalio Capital Management, and Cytokinetics. Proceeds will fund the continued clinical development of ninerafaxstat, Imbria's first-in-class cardiovascular therapy currently in a Phase 2b trial for symptomatic non-obstructive hypertrophic cardiomyopathy, a disease with no approved treatments. As part of the financing, Dr. Zina Affas Besse of AXA IM Alts and Mr. Ken Horne of AN Ventures have been appointed to Imbria's Board of Directors.ImbriaImbria Pharmaceuticals Announces Extension of Series B Financing to Advance Ninerafaxstat for Cardiovascular DiseasesImbria Pharmaceuticals announced that AXA IM Alts has joined its upsized Series B financing round to advance ninerafaxstat, a first-in-class cardiovascular therapeutic designed to improve cardiac energetics, with Dr. Zina Affas Besse and Mr. Ken Horne appointed to Imbria's Board of Directors. The proceeds will fund the ongoing FORTITUDE-HCM Phase 2b clinical trial for ninerafaxstat in symptomatic non-obstructive hypertrophic cardiomyopathy, a disease with no currently approved treatments. The financing round was syndicated with existing investors RA Capital, SV Health Investors, Deep Track Capital, AN Ventures, Catalio Capital Management, and Cytokinetics.GlobeNewswireImbria Pharmaceuticals Partners with Hypertrophic Cardiomyopathy Association to Support FORTITUDE-HCM Trial Evaluating Ninerafaxstat for Non-Obstructive Hypertrophic CardiomyopathyImbria Pharmaceuticals announced a partnership with the Hypertrophic Cardiomyopathy Association to accelerate patient recruitment for the ongoing FORTITUDE-HCM Phase 2b clinical trial evaluating ninerafaxstat in symptomatic non-obstructive hypertrophic cardiomyopathy. The trial is enrolling approximately 165 patients globally, with enrollment underway in the US and additional sites anticipated in the EU and UK by the end of 2025. The partnership will support trial awareness through HCMA's outreach programs, conferences, and patient communications, with the study also being highlighted at the HCMA Annual Patient Meeting on October 18, 2025.Pulse 2.0Imbria Pharmaceuticals: $57.5 Million (Series B) Raised To Develop Novel Therapies For Cardiometabolic DiseasesImbria Pharmaceuticals, a clinical-stage biotechnology company developing novel therapies for cardiometabolic diseases, closed a $57.5 million Series B funding round led by Deep Track Capital with participation from AN Ventures, Catalio Capital Management, Cytokinetics, and existing investors RA Capital Management and SV Health Investors. The proceeds will advance ninerafaxstat through a Phase 2b clinical trial (FORTITUDE-HCM) in non-obstructive hypertrophic cardiomyopathy, expected to begin in Q2 2025 with topline data in late 2026. The company also appointed current Executive Chair Alvin Shih as Chief Executive Officer and Rebecca Luse, Managing Director at Deep Track Capital, to its Board of Directors.The Pharma LetterImbria secures $58 million to advance mid-stage trial for lead heart drugUS biotech Imbria Pharmaceuticals has raised $57.5 million in a Series B financing round to fund a mid-stage clinical trial of its lead drug candidate ninerafaxstat. The drug targets a form of heart muscle disease with limited treatment options, representing an unmet medical need. The financing will advance the only pipeline asset in Imbria's portfolio through clinical development.VC News DailyImbria Pharmaceuticals Pulls In $57.5M Series BImbria Pharmaceuticals closed a $57.5 million Series B financing led by Deep Track Capital, with participation from AN Ventures, Catalio Capital Management, and Cytokinetics. The company's lead product candidate, ninerafaxstat, completed Phase 2 trials in three cardiometabolic indications and was well tolerated.The Pharma LetterImbria raises $57.5 million; appoints CEOUS clinical-stage biotech Imbria Pharmaceuticals raised $57.5 million in a Seres B financing round. The company is focused on cardiometabolic diseases with high unmet need.